Learn more

FOX CHASE CANCER CENTER

Overview
  • Total Patents
    129
  • GoodIP Patent Rank
    207,331
About

FOX CHASE CANCER CENTER has a total of 129 patent applications. Its first patent ever was published in 1985. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and United States. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are GOODTCELL CO LTD, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) and CA MINISTER HEALTH & WELFARE.

Patent filings per year

Chart showing FOX CHASE CANCER CENTERs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Millman Irving 13
#2 Blumberg Baruch S 13
#3 Srinivasan Ravi 12
#4 Murphy-Boesch Joseph 12
#5 Venkateswaran Pinayur S 11
#6 Estojak Joanne 9
#7 Godwin Andrew K 8
#8 Golemis Erica A 8
#9 Law Susan F 6
#10 Seeger Christoph 6

Latest patents

Publication Filing date Title
CA2712505A1 Biomarkers for the diagnosis and treatment of pancreatic cancer
AU2007353412A1 Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
AU2004257208A1 Hexameric porphobilinogen synthase as a target for the development of antibiotics and herbicides
AU6055099A Assays and novel cellular targets for therapeutic agents to treat retroviral infection
AU3207799A Mpr-related abc transporter encoding nucleic acids and methods of use thereof
WO9943323A1 Compounds and methods for chemosensitizing multidrug resistant cells
WO9914319A1 An improved yeast interaction trap assay
AU9018598A Prognostic compositions for prostate cancer and methods of use thereof
US5935937A Compositions and methods for inducing apoptosis
WO9748720A1 Nucleic acid molecule for enhancing gene expression
AU3284597A Mismatch endonucleases and uses thereof in identifying mutations in targeted polynucleotide strands
AU1970897A Assays for detection of purine metabolites
US6004958A Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
US5869650A Dendroamide compounds and their use in chemosensitizing multidrug resistant cells
US5869245A Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
US5741646A Cell lines and methods for screening growth regulatory compounds
US5716782A Nucleic acid encoding a signal mediator protein that induces cellular morphological alterations
US5821338A Antibodies specific for OVCA DNA encoded proteins and methods for their use
US5801041A Gene associated with suppression of tumor development
US5770717A Nucleic acid encoding a stress-responsive subunit of human RNA polymerase II